• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

FDA grants Aldeyra Therapeutics orphan drug designation for ADX-2191

Article

New intravitreal injection approved to treat retinitis pigmentosa, viteoretinal lymphoma, and other rare cancers

The FDA has granted orphan drug designation to Aldeyra Therapeutics’s methotrexate for intravitreal injection (ADX-2191) for the treatment of patients with retinitis pigmentosa (RP). Currently, no approved drugs are available for the treatment of this rare illness.

Methotrexate is an inhibitor of dihydroflic reductase, which is a protein involved in the cellular activation and replication of tissues.1 RP is characterized by retinal cell death and vision loss. It is estimated to affect 82,000 to 110,000 people in the United States and approximately 1 in 4,000 people worldwide.1

The FDA’s Orphan Drug Program provides financial incentives to companies developing drugs for rare diseases and conditions. Through the program, eligible drugs can be granted tax credits and other benefits.

In related news, the company recently received FDA of ADX-2191 for the treatment of primary viteoretinal lymphoma and other rare cancers.2 It is being studied for the prevention of sclerosing keratomileus, a rare inflammatory disorder that can lead to blindness and severe retinal scarring, in addition to RP.

References

1. Aldeyra Therapeutics receives orphan drug designation from the U.S. Food and Drug Administration for ADX-2191 to treat retinitis pigmentosa. News release. August 4, 2021. Accessed August 16, 2021. https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-orphan-drug-designation-us-food-0

2. Aldeyra Therapeutics receives orphan drug designation from the U.S. Food and Drug Administration for ADX-2191 to treat primary vitreoretinal lymphoma. News release. July 20, 2021. Accessed August 16, 2021. https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-orphan-drug-designation-us-food

Related Videos
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
© 2024 MJH Life Sciences

All rights reserved.